Show simple item record

dc.contributor.authorSteck, Emelieen_US
dc.date.accessioned2015-09-04T21:41:47Z
dc.date.available2015-09-04T21:41:47Z
dc.date.issued2014-08
dc.identifier.urihttps://hdl.handle.net/2144/12974
dc.descriptionPoster presentation at REU Summer's End Research Symposium, 2014, by REU participant Emelie Steck, Emory and Henry College - John Snyder group, Kyle Strom lab mentor.en_US
dc.description.abstractChronic Hepatitis C Virus, or HCV, affects 120-150 million people worldwide. HCV causes liver disease and there is not a vaccine or an effective treatment. Previous research indicated that two compounds, SL209 and SL205, inhibited the dimerization of core, the capsid protein of HCV responsible for assembling and releasing the infectious particle2. Current research is focused on testing the effect that the structure of these compounds has on their bioactivities, so analogues with similar structures to SL209 and SL205 are being synthesized.en_US
dc.description.sponsorshipNSF REUen_US
dc.language.isoen_US
dc.rightsCC0 1.0 Universalen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.title2014 REU Poster: Synthesizing Antiviral Agents Effective Against Hepatitis C Virusen_US
dc.typePresentationen_US


This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal